Original research article

Tolerance of the vaginal vault to high-dose rate brachytherapy and concomitant chemo-pelvic irradiation: Long-term perspective

Orit Kaidar-Person^a,*, Roxolyana Abdah-Bortnyak^a, Amnon Amit^b, Alexander Nevelsky^a, Alison Berniger^a, Raquel Bar-Deroma^a, Rahamim Ben-Yosef^a, Abraham Kuten^a

^a Division of Oncology, Rambam Health Care Campus, Haifa, Israel
^b Gyneco-Oncology Unit, Rambam Health Care Campus, Haifa, Israel

**Abstract**

**Aim/background:** We sought to determine the tolerance level and complication rates of the vaginal vault to combined high-dose-rate intra-cavitary brachytherapy with concomitant chemo-radiotherapy.

**Patients and methods:** A retrospective review of medical records of all the patients who received definitive chemo-radiotherapy for cervical cancer between 1998 and 2002 was undertaken. The records were reviewed for doses and for radiation-associated early and late sequelae of the vagina, rectum and bladder. Cumulative biological effective dose was calculated for two reference vaginal surface points.

**Results:** Fifty patients were included. Average age at diagnosis was 54 years. Median follow-up was 59 months. There were no recorded instances of acute grade IV toxicity. Maximal high-dose-rate vaginal surface dose (upper central point) was 103 Gy, and maximal brachytherapy lateral surface dose was 70 Gy. Maximal cumulative biological effective dose for the lateral surface reference point was 465.5 Gy3, and the maximal cumulative biological effective dose for the superior reference point was 878.6 Gy3. There were no cases of vaginal necrosis or fistulas, and no cases of grade IV late vaginal, rectal or bladder toxicity. No correlation was found between the maximal vaginal surface dose and vaginal, rectal or bladder toxicity.

**Conclusions:** The maximal surface HDR brachytherapy dose of 103 Gy and the maximal cBED of 878.6 Gy3 were not associated with fistula or necrosis or other grade 3–4 vaginal complications. Concomitant chemo-radiotherapy, including pelvic radiotherapy and high-dose-rate intracavitary brachytherapy, is relatively safe for cervical cancer patients.

© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
1. Background

The treatment of locally advanced uterine-cervix cancer includes concomitant chemo-radiotherapy and intracavitary brachytherapy as definitive treatment. Radiotherapy doses should be optimized to achieve maximal tumor control but great caution needs to be taken to avoid life-threatening or disabling early and late complications. Brachytherapy allows for creating dose escalation which is possible since the tolerance dose of the proximal vagina (vault), uterine-cervix and uterus is high.\(^1\text{,}^2\)

Numerous factors need to be taken into account when planning the treatment, apart from the patient’s habitus and tumor configuration. Procedural factors associated with source placement are often important factors affecting outcome. Vaginal shortening can occur during treatment; therefore, doses to more distal areas of the vagina, which are considered to be less tolerant than the proximal vagina, may increase during treatment.\(^3\) These factors may prevent the use of optimal brachytherapy, smaller applicators and mini ovoids, which might cause the vaginal vault mucosa tolerance dose to become a dose-limiting factor.\(^4\) Moreover, the shift from intracavitary low-dose rate (LDR) brachytherapy to intracavitary high-dose-rate (HDR) brachytherapy has led to some uncertainty. As opposed to LDR brachytherapy, there is no standardized way to deliver HDR brachytherapy, and treatments vary considerably between institutions. Dwell time patterns change from patient to patient, to allow optimization of dose distributions according to tumor geometry.\(^4\) Fractionation of HDR with four to six fractions can be applied to achieve nominal complication rates similar to LDR. However, HDR complication rates are likely to be susceptible to minor changes of dose and biological parameters, due to the amplified biological effects.\(^5\)

The development of complications is multifactorial and includes medical comorbidities, total dose of radiation, dose per fraction, number of fractions, dose rate, radiation field, radiation technique, and whether surgery was performed prior to radiotherapy.\(^1\) There are only a few reports of vaginal necrosis secondary to radiotherapy, most reported in patients treated with adjuvant concomitant chemoradiotherapy.\(^5\text{–}^7\) Publications often lack important components of treatment planning, doses, vaginal surface dose, complications, treatment failure, and other vital clinical data.\(^8\) Since the advent of 3D planning, the rectum and bladder have been given new restrictions according to volume, while the vaginal vault tolerance dose is still in the dark. Moreover, definitive treatment for cervical cancer includes concomitant chemotherapy and external beam radiotherapy (EBRT) together with HDR brachytherapy, and all should be taken into account when calculating the exposed doses of the mucosa (vagina, rectum, and bladder). The addition of chemotherapy is expected to narrow the therapeutic window when combined treatment is applied. More studies are needed to evaluate the outcome of definitive treatment for uterine-cervix cancer, encompassing both detailed dosimetric and clinical aspects of treatment, to serve as a guide for non-compromising treatment of this potentially curable disease.\(^1\)

Severe complications after radiotherapy for cervical cancer may occur decades after treatment completion.\(^6\) There is a paucity of information regarding late toxicity after chemoradiation for locally advanced cervical cancer, while total vaginal necrosis after treatment is rarely reported.\(^7\) The purpose of the current study was to determine the tolerance levels and late complication rates of the vaginal vault to combined concomitant chemotheraphy with external pelvic irradiation and intracavitary HDR brachytherapy, mostly late occurring vaginal necrosis. Complications of adjacent organs were also recorded, as well as survival, recurrences and other clinical data.

2. Patients and methods

A single center, retrospective study of the medical records of all consecutive patients with carcinoma of the uterine cervix treated between May 1998 and May 2002 with concomitant external beam radiotherapy, weekly chemotherapy, and intracavitary HDR brachytherapy was conducted. All the patients were treated with curative intent.

The medical records of 50 consecutive locally advanced patients were reviewed for radiotherapy doses and radiation-associated late sequelae of the proximal vagina (vault) with an emphasis on late-occurring vaginal necrosis. Complications of the rectum and bladder were also recorded. Vaginal patency was graded according to vaginal examination recorded in the medical files. The recorded examinations were reviewed and scored by an oncogynecologist into four levels (level 0 – no toxicity; 1 – mild; 2 – moderately obliterated and shortened vagina; level 3 – complete vaginal obliteration). Vaginal, rectal and bladder toxicity were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (September 2009). Data collected included demographics, follow-up, time and site of recurrence, mortality, sexual activity, and the presence and site of other malignancies.

The HDR planning process was based on 2D planning. In order to evaluate the doses received by the vaginal mucosa, two sets of points were defined for each ovoid: 5 points on the uppermost and 5 points on the lateral surface of the ovoid opposite the five active dwell positions at a distance equal to the radius of the ovoid. For each patient, the total vaginal dose for the whole HDR treatment was calculated on the surface of the ovoids at the lateral and the upper central point according to the method in our previous publication by Nevelsky et al.\(^9\)

\[
\text{cBED} = \text{BED}_{\text{EBRT}} + \text{BED}_{\text{HDR}} = n_d \text{BED}_{\text{EBRT}} [1 + (d_{\text{EBRT}}/\beta)] + n_d \text{BED}_{\text{HDR}} [1 + (d_{\text{HDR}}/\beta)]
\]

Fig. 1 – Equation used for calculation of cumulative biological effective dose (cBED). HDR: high-dose-rate brachytherapy; EBRT: external beam radiotherapy. The \(\alpha/\beta\) ratio used was 3 for late responding tissue.
The cumulative biological effective dose (cBED) was calculated for two reference vaginal surface points. The equation used for calculation for cBED is presented in Fig. 1. The α/β ratio used was 3 for late responding tissues. The total physical dose was calculated as the sum of the physical external dose and the physical maximal brachytherapy dose (as calculated according to the above cited method).

3. Statistical analysis

The statistical software package used was SPSS-18. Descriptive statistics are presented in terms of mean and median. As the maximal total dose and the maximal brachytherapy dose were not normally distributed by the Kolmogorov–Smirnov Z test, the Mann–Whitney U test and Kruskal–Wallis test were used for differences between groups. A value of $P < 0.05$ was considered as significant.

4. Results

Patients. Average age at diagnosis of the 50 consecutive patients who comprised the study population was 54.3 ± 12.9 years (range, 30–87 years). Median follow-up was 59 months (range, 4–132 months). Patient characteristics are summarized in Table 1. In two patients, the initial planned treatment was surgery but, due to the extent of the disease found during the procedure, it was decided to abort the operation and the patients were referred for definitive chemo-radiotherapy. One patient underwent surgery due to a pelvic abscess, and the diagnosis of cervical cancer was established during this procedure; this patient underwent unilateral salpingo-oophorectomy due to the proximity to the abscess and then was referred for definitive chemo-radiotherapy. Seven patients were lost to follow-up for evaluation of long-term toxicity; however, data of overall survival were available for all the patients and was based on the results of the population census as recorded in the population registry of the Ministry of the Interior.

<table>
<thead>
<tr>
<th>Table 1 – Patients’ characteristics ($n = 50$).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n of patients</strong></td>
</tr>
<tr>
<td>Histology</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>FIGO stage</td>
</tr>
<tr>
<td>1B1</td>
</tr>
<tr>
<td>1B2 bulky</td>
</tr>
<tr>
<td>2B</td>
</tr>
<tr>
<td>3B</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
<tr>
<td>Grade</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

Treatment. Forty-eight patients received concomitant chemo-radiotherapy (pelvic EBRT) followed by HDR brachytherapy. One patient received EBRT and HDR brachytherapy without chemotherapy because of Crohn’s disease. One patient received concomitant chemo-radiotherapy (pelvic EBRT) at a different institution; the chemotherapy regimen given was not documented in the medical record. For all patients, EBRT was performed prior to HDR brachytherapy. Cisplatin at a dose of 40 mg/m² was used concomitantly with pelvic irradiation in all except two patients in whom carboplatin was used (area under the curve of 2) due to renal insufficiency. Not all the patients received the planned chemotherapy cycles: acute gastrointestinal toxicity (diarrhea) was the main indication to discontinue chemotherapy.

EBRT. Patients were planned to be treated with external radiotherapy to the pelvis at a dose of 45–50.4 Gy (25–28 fractions, 1.8 Gy per fraction, 5 fractions per week) using 6 MV or 18 MV beams from a Varian Clinac 1800 linear accelerator (Varian Medical Systems, Inc., Palo Alto CA), according to our department’s protocol. The actual doses were 39.6–50.4 Gy (average, 45–47 Gy). Four patients received 46 Gy, 2 Gy per fraction. Depending on the patient’s body habitus, either two opposing (anterior–posterior) fields (true for most patients) or the 4-field box technique (for larger body habitus) were used. Twenty-one (42%) patients had gross parametrium involvement and an EBRT boost was added. Median boost dose was 10 Gy given as 2 Gy per fraction, 5 fractions per week (range, 5.4–10 Gy). The boost was given with a central block in the vagina and uterine–cervix area.

HDR brachytherapy. HDR brachytherapy was performed using the MicroSelectron system (Nucletron, an Elekta company (Elekta AB, Stockholm, Sweden) using Ir¹⁹² source. Prior to the first HDR brachytherapy fraction, patients underwent intrauterine stent insertion. Brachytherapy was performed with gauze packing. Intrauterine applications were performed in the lithotomy position. Nucletron (Elekta) “Fletcher-Suit like” tandem and ovoid applicators were used, with tandem curvatures of 15°, 30°, or 45°, and ovoid cap diameters of 16, 20, or 25 mm. The HDR fractionation scheme was planned for five fractions of 5–5.5 Gy each (depending on clinical evaluation of the tumor size). The Nucletron (Elekta) PLATO BPS V.13.7 treatment planning system was used. Treatment doses were prescribed at point “A”. Doses according to the International Commission on Radiation Units and Measurements (ICRU) rectal and bladder reference points, and point “B” doses (ICRU Report 38) were recorded for each treatment. As a standard, five active dwell positions separated by 5 mm steps were used in each ovoid to reproduce a traditional 2 cm LDR Gy source. Manual optimization of dwell times was performed in both the “ovoids” and the “tandem” to minimize rectal and bladder doses while retaining the traditional “pearshape” dose distribution. Brachytherapy sessions were conducted once a week. Two patients did not complete five HDR brachytherapy sessions (3 and 4 sessions out of 5 planned sessions). In the patient who received three HDR sessions, the intrauterine stent was displaced after the third session; she was given another single LDR fraction of 18 Gy to point “A”. One patient received four sessions of 6.25 Gy and another patient received five sessions of 5.9 Gy.
Fig. 2 – Brachytherapy doses for the lateral ovoid point and the upper central point (cGy).

Fig. 3 – Cumulative biological effective dose (cBED) for all patients (Gy3).

Fig. 2 summarizes the brachytherapy doses for the lateral ovoid point and the maximal brachytherapy point (upper central point) for each patient. The maximal HDR vaginal surface dose (upper central point) was 103 Gy. The maximal brachytherapy lateral surface dose was 70 Gy.

Cumulative biological effective dose. The cBED for all patients is presented in Fig. 3. The cBED calculated using the lateral surface reference point was a median of 269 Gy3 (range, 168.5–465.5 Gy3). The cBED calculated using the upper central reference point was 368.5 Gy3 (range, 226–878.6 Gy3).

Vaginal, rectal and bladder toxicity. Seven patients were lost to follow-up for evaluation of long-term toxicity. There were no fistulas (recto-vaginal or cysto-vaginal) or CTCAE grade IV late vaginal, rectal or bladder toxicity. Rectal and bladder toxicity are summarized in Table 2. There were no cases of necrosis of the distal vagina or vaginal vault. No relationship was found between the total physical dose of EBRT plus HDR or maximal HDR brachytherapy dose and the severity of vaginal, rectal or bladder complications (P = NS).

Detailed vaginal examinations recorded in the medical files, which enabled the assessment of late vaginal patency (>12 months), were available for 25 patients: 7 (28%) patients had no obliteration, 7 (28%) patients had mild shortened vagina, 7 (28%) patients had moderately obliterated and shortened vagina, and 4 (16%) patients suffered from complete vaginal obliteration.

Data of intercourse were available for 12 patients during long-term follow-up (>12 months), and four of these patients indicated being sexually active. Eight patients indicated that they were not sexually active, four due to partner issues (partner’s medical condition or no partner). One patient indicated that she suffered from dyspareunia.

Reurrence, second malignancy and overall survival. Thirteen patients had recurrent disease, nine of whom had distant recurrences. Two patients were staged at diagnosis as FIGO 1B2 bulky disease, two were FIGO 2B, and five patients were FIGO 3B. Nine of 43 (20%) patients had a second primary malignancy. In two patients, the secondary malignancy was within the irradiation field: one patient had a bladder carcinoma in situ and one patient was diagnosed with ovarian cancer one year after completion of treatment. Overall survival rate was 25% for 50 patients.

Table 2 – Late rectal and bladder complications.

<table>
<thead>
<tr>
<th>CTCAE grade</th>
<th>Urinary</th>
<th>Gastrointestinal</th>
<th>n of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Macroscopic hematuria</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Cystitis&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Urinary incontinence</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>CTCAE grade&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>n of patients</td>
</tr>
<tr>
<td>1–2</td>
<td>Diarrhea</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Proctitis&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>One patient had grade 3 proctitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Incomplete bowel obstruction</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Notes: No correlation was found to total physical dose of EBRT and HDR or maximal HDR brachytherapy dose (P = NS).
<sup>a</sup> Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
<sup>b</sup> Proven by endoscopy.

5. Discussion

In the current study, the tolerance dose of the vaginal vault and late complications were assessed based on clinical data of 50 patients. Median follow-up was 59 months, as a tertiary institution some patients after a period of time (usually 5 years) are referred back to their community physician. The maximal surface HDR brachytherapy dose of 103 Gy and the maximal cBED of 878.6 Gy3 were not associated with fistula or necrosis or other grade 3–4 vaginal complications. These findings are similar to those reported by Toita et al.<sup>11</sup> In their study, there were no cases of vaginal ulceration, fistula or necrosis at a median follow-up of 48 months with a vaginal cBED ranging from 185.5 to 618 Gy3 (median, 324 Gy3). The cBED in that study was calculated according to the dose prescribed to point “A”,

...
which is probably lower than the calculated vaginal surface
dose which was used to calculate cBED in the current study. A
retrospective analysis of 222 consecutive patients receiv-
ing radical treatment for invasive cervical cancer reported a
higher rate of recto-vaginal cases of fistula, the investiga-
tors found a strong association between the risk of develop-
ing a fistula and the BED at rectal reference point.12

The sum of physical doses of EBRT (without the boost) and
maximal HDR dose in the current study was 148 Gy. This sum
of physical doses was conducted for a “historical control” and
should not be used in practice.1,2 However, the value is similar
to that reported by Au and Grigsby1 for LDR brachyther-
apy.

No correlation was found between the values of the max-
imal HDR surface doses calculated and vaginal, rectal or
urinary complications, indicating that these complications
might follow a stochastic model.

Radiobiologically wise, HDR-brachytherapy is expected
to result in more normal tissue toxicity than LDR-
brachytherapy.13 Yet our study had similar complication rates
to those reported by Au and Grigsby1 for LDR brachytherapy.
In that study as well, there were no grade 4 complications. In
the current study, all patients were treated by using tandem
and ovoid applicators. More studies are needed to evaluate
the doses when a ring applicator is used, as it may result in
a slightly narrower distribution, leading to a higher vaginal
dose and potentially higher toxicity.14

The primary endpoint of our study was the evaluation of
late vaginal toxicity (primary – vaginal necrosis) according to
the HDR intracavitary brachytherapy doses that were given.
The cBED was calculated based on both external beam dose
and HDR-brachytherapy dose. When using the lateral surface
reference point, the cBED was a median of 269 Gy3 (range,
168.5–465.5 Gy3) and the cBED calculated using the upper
central reference point was 368.5 Gy3 (range, 226–878.6 Gy3)
without vaginal cuff necrosis and/or fistula, at a median
follow-up of 59 months. Our study indicates that the vagi-
 nal vault tolerance to HDR intracavitary brachytherapy is high,
similar to the reports of Au and Grigsby1 for LDR brachyther-
apy. It seems that the tolerance of the vaginal cuff is greater
than cBED of 368.5 Gy3. However, the study has a small patient
population and conclusions should be drawn with caution.

We also reported the rates of vaginal obliteration; however,
we do not consider this as an endpoint for estimating vagi-
 nal vault tolerance. The development of vaginal obliteration
also depends on other cofactors, such as vaginal involvement,
length of the treated vagina, vaginal washings after treatment,
regular dilation, sexual activity, etc. Owing to the retrospective
nature of this study, this information was only partially avail-
able. In our practice, all patients are routinely instructed to use
vaginal dilators. Vaginal obliteration in this young patient pop-
ulation is a disabling side effect, and efforts should be made
to avoid this complication.

Combinations of dose-specification methods, insertion
techniques and normal tissue dose relationships from differ-
ent clinical systems can be dangerous and should be avoided.
There are many differences between HDR treatment plans
and it is very challenging (or impossible) to evaluate a true
biological–clinical effect. Thus, there is a need for a spec-
trum of maximal surface doses that are safe without causing
vaginal-vault necrosis and acceptable long-term complication
rates. Hopefully, data of long-term follow-up of 3D image-
guided brachytherapy will be available in the near future to
aid in the determination of appropriate tolerance levels of the
vaginal mucosa.

Although our study is a retrospective report of 2D tech-
nique, it should be emphasized that 2D is still employed
in some countries in which this disease is prevalent. Since
our data provide spatial information of maximal dose, it
is of utmost importance, as this information is not pro-
vided by the DVH. According to our study, the maximal
surface HDR brachytherapy dose of 103 Gy and the maximal
cBED of 878.6 Gy3 were not associated with fistula or necro-
sis or other grade 3–4 vaginal complications. Concomitant
chemo-radiotherapy, including pelvic radiotherapy and high-
dose-rate intracavitary brachytherapy, is relatively safe for
cervical cancer patients.

Conflict of interest
None declared.

Financial disclosure
None declared.

Acknowledgements
The authors thank Mrs. Ronit Leiba MA, Biostatistician, Qual-
ity Improvement Unit, Rambam Health Care Campus, Haifa,
Israel, for her statistical help.

REFERENCES

1. Au SP, Grigsby PW. The irradiation tolerance dose of the
Early development of vaginal shortening during radiation
therapy for endometrial or cervical cancer. Int J Gynecol Cancer
different dose specification methods for high-dose-rate
intracavitary radiation for treatment of cervical cancer. Int J
5. Micha JP, Goldstein BH, Rettenmaier MA, Caillouette JT, Fee
MJ, Brown 3rd JV. Pelvic radiation necrosis and osteomyelitis
following chemoradiation for advanced stage vulvar and
6. Gelrich J, Hakenberg OW, Oehlschlager S, Wirth MP.
Manifestation, latency and management of late urological
complications after curative radiotherapy for cervical
necrosis following chemoradiation for advanced cervical
M. Total vaginal necrosis: a representative example of
underreporting severe late toxic reaction after concomitant
chemoradiation for cervical cancer. *Int J Gynecol Cancer* 2010;20:54–60.